---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-002411"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:26:42.065773+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neuronetics Q4 revenue up 12% to $20.3M; net loss narrows to $5.4M; first positive cash flow

## Summary
- Q4 2023 revenue $20.3M (+12% YoY); full-year revenue $71.3M (+9% YoY).
- Q4 net loss $(5.4)M ($(0.19)/share) vs $(8.3)M loss a year ago; first-ever positive cash flow of $1.5M.
- U.S. treatment session revenue up 20% in Q4 to $14.9M; local consumable treatment session revenue up >33%.
- Full-year 2024 revenue guidance $78M-$80M; Q1 2024 guidance $16.7M-$17.7M.
- Launched Better Me Guarantee Provider pilot with ~100 sites; insurers reduce TMS eligibility to 2 medication failures.

## SEC filing metadata
- accession: 0001558370-24-002411
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000155837024002411/0001558370-24-002411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000155837024002411/stim-20240305x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-002411
- JSON: https://secwatch.observer/filing/0001558370-24-002411.json
- Plain text: https://secwatch.observer/filing/0001558370-24-002411.txt

## Key facts
- Earnings Releases
  Neuronetics, Inc. reported three and twelve months ended December 31, 2023 results: revenue $20.3 million; $71.3 million, net income $(5.4) million; not stated for full year, EPS $(0.19) per share; not stated for full year.
  - Period: three and twelve months ended December 31, 2023
  - Revenue: $20.3 million; $71.3 million
  - Net income: $(5.4) million; not stated for full year
  - EPS: $(0.19) per share; not stated for full year
  - Result: reported results
  source text: in the world, today announced its financial and operating results for the fourth quarter and full year of 2023. Fourth Quarter 2023 Highlights ● Fourth quarter 2023 revenue of $20.3 million, a 12% increase as compared to the fourth quarter 2022 ● U.S. NeuroStar Advanced Therapy system revenue of $4.5 million, in the quarter, the Company shipped 59 systems ● Achieved
  evidence_url: https://www.sec.gov/Archives/edgar/data/1227636/000155837024002411/0001558370-24-002411-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.